TRCT
SBIO icon

Tower Research Capital (TRC)’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$3.3K – 5705
2024
Q4 		$3.3K Hold
100
– – ﹤0.01% 4672
2024
Q3 		$3.73K Hold
100
– – ﹤0.01% 4780
2024
Q2 		$3.36K Hold
100
– – ﹤0.01% 4898
2024
Q1 		$3.58K Hold
100
– – ﹤0.01% 4835
2023
Q4 		$3.29K Hold
100
– – ﹤0.01% 5095
2023
Q3 		$2.72K Hold
100
– – ﹤0.01% 5109
2023
Q2 		$3.15K Hold
100
– – ﹤0.01% 5100
2023
Q1 		$3K Hold
100
– – ﹤0.01% 5235
2022
Q4 		$3K Sell
100
-22,456
-100% -$676K ﹤0.01% 5225
2022
Q3 		$680K Sell
22,556
-13,198
-37% -$417K 0.01% 909
2022
Q2 		$990K Buy
35,754
+4,438
+14% +$127K 0.02% 691
2022
Q1 		$1.05M Buy
31,316
+15,844
+102% +$549K 0.01% 770
2021
Q4 		$653K Sell
15,472
-3,013
-16% -$134K 0.01% 936
2021
Q3 		$842K Sell
18,485
-33,470
-64% -$1.54M 0.02% 642
2021
Q2 		$2.54M Buy
51,955
+39,956
+333% +$1.91M 0.07% 239
2021
Q1 		$603K Buy
11,999
+991
+9% +$54.9K 0.01% 1078
2020
Q4 		$564K Sell
11,008
-39,315
-78% -$1.87M 0.02% 898
2020
Q3 		$2.07M Buy
50,323
+41,409
+465% +$1.71M 0.02% 369
2020
Q2 		$373K Sell
8,914
-783
-8% -$30.9K 0.02% 1260
2020
Q1 		$307K Buy
9,697
+1,348
+16% +$51.6K 0.02% 597
2019
Q4 		$353K Sell
8,349
-15,895
-66% -$590K 0.03% 387
2019
Q3 		$765K Buy
24,244
+1,624
+7% +$57.1K 0.05% 381
2019
Q2 		$817K Buy
22,620
+84
+0.4% +$2.9K 0.06% 324
2019
Q1 		$815K Sell
22,536
-3,217
-12% -$107K 0.05% 358
2018
Q4 		$725K Buy
25,753
+7,209
+39% +$239K 0.05% 331
2018
Q3 		$730K Buy
+18,544
New +$703K 0.05% 318

Other funds holding SBIO

PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
NAM
NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return
PWA
Phoenix Wealth Advisors Chapel Hill, North Carolina $253M AUM 17.97% 1-Year Est. Return

Tower Research Capital (TRC)'s SBIO Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q1 2025, closing a stake of 100 shares — an estimated $3.3K sold.

Tower Research Capital (TRC) first reported a position in SBIO in Q3 2018 and held it in 26 quarters. The position peaked at $2.54M in Q2 2021. 34 funds tracked by Wall St. Rank hold SBIO as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining ALPS Medical Breakthroughs ETF position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 100 ALPS Medical Breakthroughs ETF shares in Q1 2025, an estimated $3.3K.
  • Tower Research Capital (TRC) first reported a position in ALPS Medical Breakthroughs ETF in Q3 2018 and held it in 26 quarters.
  • Tower Research Capital (TRC)'s ALPS Medical Breakthroughs ETF position peaked at $2.54M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.